Share Name Share Symbol Market Type Share ISIN Share Description
Iofina Plc LSE:IOF London Ordinary Share GB00B2QL5C79 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.50 -2.07% 23.60 363,228 16:35:06
Bid Price Offer Price High Price Low Price Open Price
23.30 23.90 23.40 23.30 23.40
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
General Financial 23.96 -1.37 -0.90 45
Last Trade Time Trade Type Trade Size Trade Price Currency
17:09:10 O 11,398 23.30 GBX

Iofina (IOF) Latest News

More Iofina News
Iofina Takeover Rumours

Iofina (IOF) Share Charts

1 Year Iofina Chart

1 Year Iofina Chart

1 Month Iofina Chart

1 Month Iofina Chart

Intraday Iofina Chart

Intraday Iofina Chart

Iofina (IOF) Discussions and Chat

Iofina Forums and Chat

Date Time Title Posts
23/10/201920:47iofina iodine and Canabis oil1,783
22/10/201910:30IOF tipsters2,630
08/10/201913:12Iofina PLC (LON:IOF) looking to build on the successes56
18/9/201916:00Iofina44,890
31/7/201922:58IOFINA Iodine, gas, water!!, maybe Oil (Bakken)26,287

Add a New Thread

Iofina (IOF) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2019-10-23 16:09:1023.3011,3982,655.73O
2019-10-23 15:29:5723.302,905676.87AT
2019-10-23 15:29:5723.302,977693.64AT
2019-10-23 15:29:5723.305,3901,255.87AT
2019-10-23 15:02:0323.4518,0004,221.00O
View all Iofina trades in real-time

Iofina (IOF) Top Chat Posts

DateSubject
23/10/2019
09:20
Iofina Daily Update: Iofina Plc is listed in the General Financial sector of the London Stock Exchange with ticker IOF. The last closing price for Iofina was 24.10p.
Iofina Plc has a 4 week average price of 22.60p and a 12 week average price of 21.70p.
The 1 year high share price is 33.60p while the 1 year low share price is currently 10p.
There are currently 191,858,408 shares in issue and the average daily traded volume is 740,497 shares. The market capitalisation of Iofina Plc is £45,278,584.29.
04/8/2019
12:02
freddiehoward: My conservative calcs based on last years final results and latest update confirm Zendo's numbers based on PE of 15 gives a share price of 21p, increase in product shipped of 10% and increase of iodine price of 25% as per latest update. I've not used actual iodine prices, just % change. The latest update says debt is down 7.5 million which seems to be about 25% on last years debt. If I assume that the finance charge is down 25%, I get a Share price of 26p. So for me, the current price fairly values the business as it stands with no more news, but ignores any of the potential upside from additional plants, increasing iodine prices, CBD possibly higher production and margins from derivatives and non-iodine prducts. I'd expect a business with these prospects to trade on a PE of 18, which give an share price of 24p without finance charge reduction and 30p with so current share price is in the range. So for any significant jutified change/re-rating from here I'd say news is now essential. Anyway, here are my calcs laid out as in Final results. Year ended Year ended 31 December 31 December 2019 2018 Revenue from sales of iodine and iodine derivatives $20,342,077 $14,794,238 Revenue from non-iodine products $9,164,051 $9,164,051 Total revenue $29,506,128 $23,958,289 This is based on 10% increase of metric tonnes shipped from 544 to 598 and increase of iodine price by 25% (from 2019 update). Assume non-iodine remains as 2018 as I have no info on that and don't know what those products are. Can't find the COS split between iodine and non-iodine so assume they are in same proportion as sales - big assumption that can be played with. Also assume only the additional shipped volume will affect COS i.e. increased iodine price does not (it probably would because of dsales people's bonuses etc.). So non-iodine COS 2018 is 9,164,051/27,656,848 * 17,651,387 = 6,751,659 Iodine COS (2018) = $10,899,727 Iodine COS (2019 = 1.1 * $10,899,727= $11,989,700 Total COS = $18,741,360 Stick this into 2018 results Year ended Year ended 31 December 31 December 2019 2018 Note $ $ Revenue 3 29,506,128 23,958,289 Cost of sales 4 (18,741,727) (17,651,387) --------------- --------------- Gross profit 10,764,401 6,306,902 Administrative expenses 4 (5,241,033) (5,241,033) --------------- --------------- Operating profit/(loss) 5,523,368 1,065,869 Impairment expense 4 (2,592,276) (2,592,276) Finance expense 6 (3,062,982) (3,062,982) Finance income 7 974 974 Revaluation of derivative liability 19 3,214,166 3,214,166 --------------- --------------- Profit before taxation 4 3,315,719 (1,374,249) Taxation 8 0 231,233 --------------- --------------- Profit for the year attributable to owners of the parent $3,315,719 $(1,143,016) --------------- --------------- Shares in issue 191858408 EPS = 1.39p Assume PE 15 share price would be 21p Looking at update, I reckon the debt has been reduced by 25% so finance charge should be down 25%. If I do this then get a Share Price of 26p.
19/6/2019
21:44
naphar: I’ll be even more excited when we can start seeing a share price exceeding that last spike madchick. Note I am saying when and not if.i understand why Fest is saying it will take time, given all the additional shares in issue, and he might be right, but IOF share price can shift when the market dictates and I think we are in a good place for that to happen again.
09/6/2019
16:41
naphar: Well we all know IOF share price can move quickly. 64p a good target to have and would be very pleased to see that achieved!
23/5/2019
17:16
pcjoe: Ah but it is a heart warming and wonderful chart Lucky (page 15) hTTp://www.iofina.com/perch/resources/launch-announcement-final-20may2019.pdf The longest the I price per KG has lagged the underlying trend line is 10 years (2000- 2010) - we are current 4 1/2 years lagged beneath the trend line ( trend line never stopped rising since 1960) - At some point the rising KG price will converge with the trend line average and overshoot - Always has done and always will as long as Western civilisation holds steady - If it doesnt we will have more to worry about than the IOF share price open to interpretation but with price & trend convergence in 3 years time that looks like a converging point rate between $45 - $60 dollar I kg price with potential for a couple of years or more rise after that before the bull/bear cycle begins to repeat
20/5/2019
09:35
festario: What buys? Why would anyone buy above 16p?I'll put my buy order in for 16p, then I'll take my leave of this board for many months.Because that's how long it will take for IOF share price to get out of this quagmire.
14/5/2019
20:21
naphar: Wooly, I can give it a go, but I thought it was quite self explanatory. (I hope it wasn't a rhetorical question!) Since results, we have been seeing a nice rise in the share price. Yesterday afternoon things really took off. Then near the end of the day, the price pulled back a couple of pence from the peak I saw. Nothing strange in that after such a rise. Then we discovered commentary on a website that IOF was doing a fundraise at 22p. A shock to many, myself included. Then we discovered IGIndex shorts had been placed yesterday (maybe also some on Friday). I assume you read this mornings announcement. Even though the RNS suggested the share price might be rising due to the results that were announced and the beneficial impact of a rising iodine price, it left a level of doubt about the fundraise and the price it may happen at. The RNS stated the fundraise, it it goes ahead, might be at a discount to the prevailing share price. They didn't state a price, they didn't state a significant discount, but it left doubt. Share price was marked down and selling followed (along with at least some buying). I would not be surprised if the shorters have been out in force and sent the share price down even further. Now in reality, this fundraise may not even happen. Many regulars here don't believe it's really needed for expansion to begin with IO8. Sure it could happen faster through raising some more money, but I am not convinced it's really necessary for iodine expansion (CBD I have no idea). It strikes me that Iofina may not have asked for a fundraise, but interested parties may have approached Iofina; of course I don't know that, but having celebrated removing the convertible element of the debt, why would they want to dilute now?
14/5/2019
16:01
harrysol: I am extremely upset and disappointed with the iof share price today. I have lost a fair bit. What's more painful is that I came very close to selling half of my holdings yesterday. My concern is that there is further to go. I initially thought 18-19p. I am now worried it could be 15-16p. With regards to the nomad, can someone please explain to me and how they could have manipulated the iof share price?
14/5/2019
15:13
pcjoe: Iof share price - here there and everywhere it seems - whose winning - whose losing? - strange game & totally beyond my understanding
07/5/2019
15:40
camerongd53: It is great to see that Iofina has sorted themselves out operationally and have sorted out immediate cash flow difficulties. Also there is optimism about the future. I have a major concern re IOFINA In the recent sccounts there is cash etc, term loan and convertible loan notes which amount to a net liability of approx $20.3m - the net equity is $5.9m However the cashflow statement shows that cashflow was only just over $1m for last year. I know that the $1m will increase with increased production from the current production resources and higher iodine prices but in reality is it likely to increase without new wells beyond say $4m. If so it will take 5 years to clear the current debt which is quite a long time!!! Ideally Iofina will want to expand production requiring capital expenditure and increase profitability and cashflowthat way. my view is that IOfina needs a pretty hefty rights issue to improve the financial position to invest for the future. I would suggest a 1 for 2 rights issue at say 20p could raise c£5m stg /$6m. I suspect the share price is being held back because of current financial liabilities. A stronger balance sheet could actually cause the share price to rise which could be a win win. I am generally against placings as existing shareholders are generally shafted. A share price is generally riven by Dividends (or reasonable expectation of same)I feel that unless there is an expectation of dividends in the near future, the share price may stagnate. Comments splease
06/2/2019
14:24
goofy1: Company seems to have a lot of flexibility. 30 September 2016 Iofina plc ("Iofina", the "Group" or the "Company") (LSE AIM: IOF) Completion of US$20 million Convertible Secured Loan Notes Restructure and additional US$10 million Secured Facility Iofina, specialists in the exploration and production of iodine and iodine specialty chemical derivatives, is pleased to report the completion of the restructuring of convertible secured loan notes in the amounts of US$15 million to Stena Investment S.á.r.l. ("Stena") and US$5 million to Panacea Limited ("Panacea") (together, the "Notes" and the "Noteholders"). The general terms of this debt restructuring were first reported in June 2016, and the documentation between the parties has now been completed. Highlights: Restructuring of $20m Convertible Notes · Reissued as Convertible Secured Notes redeemable 1 June 2019 · Convertible in three equal tranches at 18p, 25p and 32p per share · Interest payable at 5% per annum or may be rolled-up and capitalised New $10m Secured Facility with Stena · Repayable on 1 June 2019 · Interest payable at 6% per annum · Funds to be used to support and develop the Group's iodine operations Cumulative effect of these agreements is to remove uncertainty surrounding the Group's balance sheet and funding position, and provide operational flexibility to develop the Group's iodine production and derivatives operations. Commenting on today's announcement, Dr. Thomas Becker, President & CEO of Iofina plc stated: "The Board is delighted to announce the completion of the documentation for the convertible debt restructuring and the additional debt facility, the terms of which were first announced in June. Iofina values the partnerships with Panacea and Stena and the Group now has additional resources to execute growth plans." Details of the agreements: On 29 September 2016 the Company executed two Convertible Secured Loan Note Instruments on the same terms and conditions, under which loan notes with a nominal value of US$1 each were issued to Stena in an aggregate principal amount of US$15,000,000 and to Panacea in an aggregate principal amount of US$5,000,000. These new loan Notes have refinanced and replaced in their entirety the previously issued loan notes in the same principal amounts as regards Stena and Panacea respectively. The principal terms and conditions attaching to the Notes are as follows: (a) unless previously converted into ordinary shares of £0.01 each in the capital of the Company ("Ordinary Shares") or redeemed, the Notes are redeemable at par together with capitalised, accrued and unpaid interest on 1 June 2019; (b) the Company is entitled to redeem any of the Notes at any time prior to 1 June 2019 without penalty; (c) any or all of the Notes outstanding may be converted into Ordinary Shares by the Noteholders at any time subject to prior written notice to the Company of 28 days or such shorter period as may be agreed by the Company; (d) the conversion rates to be used for the conversion of the Notes into Ordinary Shares are, as regards the total amount of the Notes outstanding, one third at 18p per share, one third at 25p per share, and one third at 32p per share; (e) the Company may require that any or all of the Notes outstanding be converted into Ordinary Shares following the publicly quoted closing price per Ordinary Share being 50p or more for at least five consecutive trading days; (f) interest is payable quarterly in arrears at the rate of 5% per annum. The Company may at its sole discretion elect to roll-up quarterly interest payments without limit, in which case the interest rolled-up will be capitalised and form part of the principal balance of the Notes; (g) the Noteholders may resolve to accept payment of any capitalised or accrued interest by the issuance of Ordinary Shares, using a conversion rate of 32p per share; (h) unless the prior consent of the Company has been obtained, the Noteholders are not entitled to sell or transfer the Notes except to certain related parties; and (i) no conversion shall be permitted in the event that, upon such conversion, it would have the effect of establishing or otherwise increasing a holding in Ordinary Shares of a Noteholder (whether by itself or in conjunction with the holdings of any "concert parties" (as defined in The City Code on Takeovers and Mergers (the "Code))) which could potentially trigger a mandatory offer having to be made for other Ordinary Shares under Rules 9 and 37 of the Code. A conversion may be so permitted if the Company and the relevant Noteholder agree to it in writing but subject at all times to the receipt of any prior written approval which may be required from The Panel on Takeovers and Mergers. The Notes are secured against the assets of the Group, by a share pledge and a debenture granted by the Company, and by further pledges, security agreement and guarantees granted by certain subsidiaries of the Company. On 29 September 2016 the Company entered into an agreement for a Term Loan Facility of up to US$10,000,000 (the "Facility") with Stena. The principal terms and conditions attaching to the Facility are as follows: (a) the Facility is to be utilised for capital expenditure and working capital purposes in connection with (i) the Company's iodine and iodine derivatives production, refinement, marketing and sales activities; (ii) water depot project; and (iii) iodine and natural gas operations, as carried out at the Company's sites in the United States of America; (b) the Company may draw down up to US$3,000,000 of the Facility on request and in tranches of not less than US$250,000 or such other amount as may be agreed; (c) drawdowns of amounts of the Facility in excess of US$3,000,000 are dependent upon completion of a detailed due diligence exercise and satisfaction with the results by Stena regarding the prevailing state of affairs relating to the Group and its assets; (d) interest is payable quarterly in arrears at the rate of 6% per annum. The Company may elect to capitalise the interest, in which case the interest will be rolled-up and treated as principal outstanding and repaid on 1 June 2019; (e) all amounts outstanding under the Facility are repayable in full on 1 June 2019; (f) the Company may repay any amounts outstanding under the Facility at any time without penalty. The Company may reborrow amounts previously repaid subject to the consent of Stena; (g) for so long as amounts are outstanding under the Facility the Company is not to make any payments to shareholders or other debt providers, including principal amounts outstanding under the Notes, without Stena's prior consent; and (h) without the prior consent of Stena, the Group is not to take on further borrowings, except for debt at an interest rate lower than the Facility rate that is used to repay amounts outstanding under the Facility. The Facility is secured against the assets of the Group under the same arrangements as set out above in relation to the Notes. Conversion premiums to current share price: The premiums over the closing price per Ordinary Share of 13.75p on 29 September 2016 represented by the conversion rates applicable to the Notes are as follows: · Stena o US$5 million at a conversion price of 18p, which represents a premium of 31% to the closing price of 13.75p on 29 September 2016; o US$5 million at a conversion price of 25p, which represents a 82% premium to the closing price of 13.75p on 29 September 2016; and o US$5 million plus any capitalised or accrued interest at a conversion price of 32p, which represents a 133% premium to the closing price of 13.75p on 29 September 2016 · Panacea o US$1.67 million at a conversion price of 18p, which represents a premium of 31% to the closing price of 13.75p on 29 September 2016; o US$1.67 million at a conversion price of 25p, which represents a 82% premium to the closing price of 13.75p on 29September 2016; and o US$1.67 million plus any capitalised or accrued interest at a conversion price of 32p, which represents a 133% premium to the closing price of 13.75p on 29 September 2016 Conversion shares percentage of enlarged share capital: Based on the par value of the Notes of US$20 million and the current GBP/USD exchange rate (and excluding any interest which may be converted) and assuming all Notes were converted, the Ordinary Shares to be issued on the conversion of the total principal amount of the Notes would represent approximately 65 million shares or approximately 34% of the then enlarged issued share capital of the Company.
Iofina share price data is direct from the London Stock Exchange
Your Recent History
LSE
IOF
Iofina
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191024 04:47:22